Anavex Life Sciences Corp (AVXL)

[McMagyar]

This is a great point and again shows the Guiding Hand to our efforts..
It is hard to let go sometimes and I think the loss of any Combo Patent made diving harder(Ariana) into the data more vital. They dropped Combo because of its lack of comparative success to A2-73 MonoTherapy.

My guess is Combo would still be on the table as SOC IF Monotherapy was not proving a major significant difference. They would still be exploring both! Why aren't they?

Not because of the failure to Patent Combo, but Mono Data is too robust to deny .
What that looks like on a poster board at CTAD .. well we will find out..